We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Perspective Therapeutics (CATX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Perspective Therapeutics is a member of the Medical sector. This group includes 914 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Perspective Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CATX's full-year earnings has moved 5.7% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, CATX has returned 9.5% so far this year. Meanwhile, stocks in the Medical group have lost about 0.4% on average. This means that Perspective Therapeutics is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Bristol Myers Squibb (BMY - Free Report) . The stock is up 21.4% year-to-date.
Over the past three months, Bristol Myers Squibb's consensus EPS estimate for the current year has increased 10.7%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Perspective Therapeutics belongs to the Medical - Drugs industry, a group that includes 136 individual companies and currently sits at #147 in the Zacks Industry Rank. This group has lost an average of 4.7% so far this year, so CATX is performing better in this area.
Bristol Myers Squibb, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 439-stock industry is ranked #101. The industry has moved +0.8% so far this year.
Perspective Therapeutics and Bristol Myers Squibb could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Perspective Therapeutics (CATX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Perspective Therapeutics is a member of the Medical sector. This group includes 914 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Perspective Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CATX's full-year earnings has moved 5.7% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, CATX has returned 9.5% so far this year. Meanwhile, stocks in the Medical group have lost about 0.4% on average. This means that Perspective Therapeutics is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Bristol Myers Squibb (BMY - Free Report) . The stock is up 21.4% year-to-date.
Over the past three months, Bristol Myers Squibb's consensus EPS estimate for the current year has increased 10.7%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Perspective Therapeutics belongs to the Medical - Drugs industry, a group that includes 136 individual companies and currently sits at #147 in the Zacks Industry Rank. This group has lost an average of 4.7% so far this year, so CATX is performing better in this area.
Bristol Myers Squibb, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 439-stock industry is ranked #101. The industry has moved +0.8% so far this year.
Perspective Therapeutics and Bristol Myers Squibb could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.